Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men | Zendy

Ashish A. Deshmukh | Zendy; Jagpreet Chhatwal | Zendy; Elizabeth Y. Chiao | Zendy; Alan G. Nyitray | Zendy; Prajnan Das | Zendy; Scott B. Cantor | Zendy

Open Access

Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men

Author(s) -

Ashish A. Deshmukh,

Jagpreet Chhatwal,

Elizabeth Y. Chiao,

Alan G. Nyitray,

Prajnan Das,

Scott B. Cantor

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ628

Subject(s) - medicine , men who have sex with men , regimen , anal cancer , human papillomavirus , human immunodeficiency virus (hiv) , vaccination , gynecology , immunology , syphilis

Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in men who have sex with men (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a 50% reduction in the risk of recurrent HGAIN. We evaluated the long-term clinical and economic outcomes of adding the qHPV vaccine to the treatment regimen for HGAIN in human immunodeficiency virus (HIV)-positive MSM aged ≥27 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research